Compare WYY & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WYY | ALXO |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.2M | 68.3M |
| IPO Year | 2005 | 2020 |
| Metric | WYY | ALXO |
|---|---|---|
| Price | $4.91 | $2.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $8.67 | $3.42 |
| AVG Volume (30 Days) | 46.2K | ★ 1.0M |
| Earning Date | 03-03-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.35 | 31.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $142,571,749.00 | N/A |
| Revenue This Year | $5.20 | N/A |
| Revenue Next Year | $15.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 34.47 | N/A |
| 52 Week Low | $2.19 | $0.41 |
| 52 Week High | $7.55 | $2.66 |
| Indicator | WYY | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 43.53 | 52.41 |
| Support Level | $2.82 | $1.41 |
| Resistance Level | $6.04 | $2.27 |
| Average True Range (ATR) | 0.43 | 0.27 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 51.08 | 23.08 |
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.